Open Access

Distinguishing between limited systemic scleroderma-associated pseudo-obstruction and peritoneal dissemination

  • Susumu Saigusa1, 2Email author,
  • Yasuhiro Inoue1, 2,
  • Masaki Ohi1, 2,
  • Hiroki Imaoka1, 2,
  • Ryo Uratani1, 2,
  • Minako Kobayashi1, 2 and
  • Masato Kusunoki2
Surgical Case Reports20151:21

DOI: 10.1186/s40792-014-0010-4

Received: 6 November 2014

Accepted: 22 December 2014

Published: 24 February 2015

Abstract

A 78-year-old woman receiving treatment for limited systemic scleroderma (SSc) underwent high anterior resection and partial liver resections for rectosigmoid colon cancer with multiple liver metastases. A year after surgery, an abdominal computed tomography (CT) demonstrated suspicion for peritoneal dissemination with an increase in ascites, and 18F-fluorodeoxy glucose-positron emission tomography-CT was suggestive of carcinomatosis. We began to decompress the small intestine and administer octreotide. However, the intestinal obstruction did not improve. Although intestinal pseudo-obstruction caused by limited SSc was considered as a differential diagnosis, we performed an exploratory laparotomy because the possibility of peritoneal dissemination-associated obstruction could not be excluded. We observed a moderate amount of serous ascites and dilatation of the small intestine that was white in color, hard, and with limited contractility. There was no evidence of peritoneal dissemination nor of mechanical obstruction. Our experience thus shows the difficulty of distinguishing SSc-associated intestinal pseudo-obstruction from peritoneal dissemination.

Keywords

Pseudo-obstruction Peritoneal recurrence Limited systemic scleroderma FDG PET-CT

Background

Intestinal pseudo-obstruction is caused by several diseases including connective tissue disorders, hypothyroidism, Chagas’ disease, diabetes, and Parkinson’s disease. Systemic scleroderma (SSc) is a chronic disorder of the connective tissue characterized by inflammation, fibrosis, and degeneration of the skin and blood vessels and is known to cause intestinal pseudo-obstruction [1-5]. The radiographic findings of intestinal pseudo-obstruction caused by SSc are a hide-bound bowel sign or accordion sign on abdominal X-ray or contrast study and pneumatosis cystoides intestinalis on abdominal computed tomography (CT) [3,6-8]. However, these findings cannot exclude mechanical obstruction such as that caused by postoperative adhesions or peritoneal dissemination. Although 18F-fluorodeoxy glucose-positron emission tomography (FDG PET-CT) is a useful tool to detect peritoneal metastases, low-grade FDG uptake should be carefully assessed because it is difficult to differentiate inflammation or fibrotic change from tumor recurrence [9-12]. We report a case in which it was difficult to distinguish between SSc-associated pseudo-obstruction and peritoneal dissemination in a SSc patient after surgery for stage IV colon cancer.

Case presentation

A 78-year-old woman receiving treatments including the administration of low dose of corticosteroid and proton pump inhibitor for LSSc (antinuclear antibody: positive; anti-centromere antibody: positive; anti-topoisomerase antibody: negative; anti-ribonucleoprotein antibody: negative) for 7 years underwent high anterior resection and partial liver resections for rectosigmoid colon cancer with multiple liver metastases (S4, S6, and S8). The preoperative serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9) were 7.9 ng/ml (normal range, ≤5.8 ng/ml) and 85.7 U/ml (normal range, 0 to 37.0 U/ml). Pathological findings showed well-differentiated tubular adenocarcinoma, T3N1M1 with lymphatic invasion. On partial resection for each liver metastasis, S4 lesion resulted in positive resection margin. Although she received adjuvant therapy (capecitabine plus oxaliplatin) for 6 months after surgery, she stopped the therapy because of the side effects. A year after the surgery, an abdominal CT demonstrated suspected peritoneal dissemination with increased ascites (Figure 1A). Tumor markers were not increased (both CEA and CA19-9 were within normal range), but the ascites was increasing and obstructive symptoms such as nausea, emesis, and abdominal distension worsened. Contrast study showed delayed transit through the small intestine with eventual movement into the colon. To confirm whether or not there was any evidence of tumor recurrence, we performed FDG PET-CT, which suggested peritonitis carcinomatosa with diffuse low-grade FDG uptake along the small intestinal wall (Figure 1B). We began to decompress the small intestine and administer octreotide. However, the intestinal dilatation and stasis did not improve (Figure 2). Although pseudo-obstruction caused by LSSc was considered as a differential diagnosis, we performed an exploratory laparotomy because the possibility of partial obstruction caused by peritoneal dissemination could not be excluded and the patient failed to improve with conservative measures. Preoperative laboratory investigation revealed anemia (hemoglobin 9.6 g/dl), mild elevated liver enzymes (aspirate aminotransferase 43 IU/l, alanine aminotransferase 47 IU/l), and poor nutritional condition (total protein 4.9 g/dl, albumin 2.9 g/dl).Upon laparotomy, we observed a moderate amount of serous ascites and dilatation of the small intestine overlying which was a whitish film. The bowel was hardened, with wall thickness and limited contractility, similar to findings in encapsulating peritoneal sclerosis (Figure 3A,B). Its findings were observed in all the small intestine. However, there was no evidence of peritoneal dissemination or mechanical obstruction. Eventually, we performed an enterostomy and sampling of the small intestinal serosa. On histopathological examination, fibrotic change in the muscle and serosal layers was observed (Figure 3C). Postoperatively, we administrated neostigmine bromide as a substitute for octreotide (not approved for this indication in Japan) and erythromycin to promote intestinal motility, but these treatments were not effective. We treated her with the decompression of the small intestine via enterostomy for stasis and total parenteral nutrition for stasis-related malabsorption and malnutrition. However, her general condition such as anasarca induced by malnutrition was gradually worse. Ultimately, she suffered from sepsis caused by stasis-related bacterial overgrowth and translocation, and died on postoperative day 77.
Figure 1

Increase in ascites and diffuse low-grade FDG uptake. Abdominal CT shows an increase in ascites and mild thickness of the small intestinal wall (A). Diffuse low-grade FDG uptake along the small intestinal wall (white arrows) (B).

Figure 2

Abdominal X-ray before surgery. Upright position (A), supine position (B).

Figure 3

Operative and histopathological findings. Dilatation and hardening of the small intestine (A). Diffuse fibrotic change throughout the small intestine (B). Fibrotic change in the muscle and serosal layers (C). Hematoxylin and eosin stain, original magnification × 40.

Conclusions

Gastrointestinal involvement is the most common non-dermatologic complication in patients with SSc [3,13]. Gastrointestinal dysfunction can severely and negatively impact quality of life and is associated with a poor prognosis [14-18]. Limited SSc is a subtype of systemic scleroderma that was previously referred to as CREST syndrome (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias). Patients with limited SSc develop sclerosis of the skin distal to their elbows, knees, and face and are more likely to develop pulmonary hypertension. Patients with another subtype of SSc, diffuse SSc, develop not only distal but also proximal sclerosis and tend to have more significant visceral organ involvement than those with limited SSc. However, gastrointestinal involvement is common in both subtypes and the severity of cutaneous and gastrointestinal manifestations often does not correlate [3,19,20]. Pathologic manifestations in patients with SSc are due to progressive fibrosis of intestinal smooth muscle. Physiologically, inflammation of the myenteric ganglia and fibrosis of gastrointestinal muscle have been found in patients with SSc [21,22]. Small intestinal hypomotility causes luminal dilatation and stasis of luminal contents resulting in a pseudo-obstruction, leading to stasis-related malabsorption. Secondary small intestinal bacterial outgrowth affects almost half of patients with SSc [5,23-25]. It has been reported that octreotide is the most potent prokinetic drug for pseudo-obstruction [26,27]. However, octreotide did not improve motility in the present case. Moreover, erythromycin, which mimics motilin, known as the prokinetic hormone, was also not effective, despite the fact that several authors have reported upon its effectiveness for pseudo-obstruction [28,29]. We think that the lack of effectiveness of these drugs is due to the progressive fibrosis of the small intestine and malabsorption by small intestinal bacterial overgrowth. Although we tried enteral nutrition in the form of an elemental diet via the enterostomy with concomitant administration of antibiotics such as metronidazole [30,31], the nutrition status of our patient did not improve. We think that early diagnosis and treatment for pseudo-obstruction is important, along with the collaboration of rheumatologists and gastroenterologists in patients with gastrointestinal involvement of SSc. Although we lack a complete understanding of the progressive nature of the disease, the presence of carcinoma in addition to adjuvant chemotherapy may compound the situation [32].

On radiographic examination, abdominal X-ray did not show the typical appearance of SSc-associated pseudo-obstruction such as the hide-bound bowel sign [3,6-8]. Although we observed pneumatosis cystoides intestinalis in the descending colon 2 months before exploratory laparotomy, this finding was not noted during the surgery. Given the increase in ascites and occurrence of obstructive symptoms, most would suspect peritoneal recurrence in a patient with stage IV colon cancer after surgery. FDG PET-CT has the potential to improve detection of peritoneal carcinomatosa [9-12]. However, FDG uptake is also present in cases of fibrosis and inflammation, and it is difficult to distinguish this pathology from peritoneal metastasis [9-12]. Although diffuse low-grade FDG uptake (up to the maximum standardized uptake value of 2.3) along the small intestinal wall was observed, we were unable to definitively diagnose the current case as one of intestinal pseudo-obstruction. Several authors reported that evaluation for radiation-induced fibrosis and retroperitoneal fibrosis is helpful [33-35]. On the other hand, Nishiyama et al. have reported that FDG PET-CT is useful to evaluate the degree of disease associated with connective tissue disorder [36]. In the current case, we think that elevated FDG uptake along the small intestinal wall was indicative of inflammation and fibrosis.

In conclusion, our experience suggests that it is difficult to distinguish LSSc-associated intestinal pseudo-obstruction from peritoneal dissemination. Although FDG PET-CT is an effective tool for detection of peritoneal metastasis, comprehensive assessment of the findings in a patient with both SSc and advanced gastrointestinal cancer is necessary.

Consent

Written informed consent was obtained from the patient’s husband for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Declarations

Authors’ Affiliations

(1)
Department of Surgery, Wakaba Hospital
(2)
Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine

References

  1. Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol. 1996;8:569–75.View ArticlePubMedGoogle Scholar
  2. Connor FL, Di Lorenzo C. Chronic intestinal pseudo-obstruction: assessment and management. Gastroenterology. 2006;130:S29–36.View ArticlePubMedGoogle Scholar
  3. Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci. 2008;53:1163–74.View ArticlePubMedGoogle Scholar
  4. Munoz-Yague MT, Solis-Munoz P, Salces I, Ballestin C, Colina F, Ibarrola C, et al. Chronic intestinal pseudo-obstruction: a diagnosis to be considered. Rev Esp Enferm Dig. 2009;101:336–42.View ArticlePubMedGoogle Scholar
  5. Savarino E, Mei F, Parodi A, Ghio M, Furnari M, Gentile A, et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford). 2013;52:1095–100.View ArticleGoogle Scholar
  6. Pickhardt PJ. The “hide-bound” bowel sign. Radiology. 1999;213:837–8.View ArticlePubMedGoogle Scholar
  7. Hokama A, Ihama Y, Kishimoto K, Yara S, Kinjo F, Fujita J. Clinical images: chronic intestinal pseudoobstruction and the “hide-bound” bowel sign. Arthritis Rheum. 2007;56:1724.View ArticlePubMedGoogle Scholar
  8. Seket B, Kaczmarek D, Tiffet O. Intestinal pseudo-obstruction and pneumatosis cystoides intestinalis in a scleroderma patient. J Am Coll Surg. 2007;205:180–1.View ArticlePubMedGoogle Scholar
  9. De Gaetano AM, Calcagni ML, Rufini V, Valenza V, Giordano A, Bonomo L. Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging. 2009;34:391–402.View ArticlePubMedGoogle Scholar
  10. Anthony MP, Khong PL, Zhang J. Spectrum of (18)F-FDG PET/CT appearances in peritoneal disease. AJR Am J Roentgenol. 2009;193:W523–9.View ArticlePubMedGoogle Scholar
  11. Puranik AD, Purandare NC, Agrawal A, Shah S, Rangarajan V. Imaging spectrum of peritoneal carcinomatosis on FDG PET/CT. Jpn J Radiol. 2014;32:571–8.View ArticlePubMedGoogle Scholar
  12. Buscombe J. PET imaging of inflammation. Q J Nucl Med Mol Imaging. 2014;58:284–9.PubMedGoogle Scholar
  13. Szamosi S, Szekanecz Z, Szucs G. Gastrointestinal manifestations in Hungarian scleroderma patients. Rheumatol Int. 2006;26:1120–4.View ArticlePubMedGoogle Scholar
  14. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol. 2001;28:2454–9.PubMedGoogle Scholar
  15. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002;81:154–67.View ArticleGoogle Scholar
  16. Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437–44.View ArticlePubMedGoogle Scholar
  17. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford). 2009;48 Suppl 3:36–9.Google Scholar
  18. Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol. 2013;25:700–6.View ArticlePubMedGoogle Scholar
  19. Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol. 2013;31:432–7.View ArticlePubMedGoogle Scholar
  20. Di Ciaula A, Covelli M, Berardino M, Wang DQ, Lapadula G, Palasciano G, et al. Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma. BMC Gastroenterol. 2008;8:7.View ArticlePubMed CentralPubMedGoogle Scholar
  21. Malandrini A, Selvi E, Villanova M, Berti G, Sabadini L, Salvadori C, et al. Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases. J Rheumatol. 2000;27:1203–6.PubMedGoogle Scholar
  22. Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55:1697–703.View ArticlePubMed CentralPubMedGoogle Scholar
  23. Marie I. Gastrointestinal involvement in systemic sclerosis. Presse Med. 2006;35:1952–65.View ArticlePubMedGoogle Scholar
  24. Sjolund K, Bartosik I, Lindberg G, Scheja A, Wildt M, Akesson A. Small intestinal manometry in patients with systemic sclerosis. Eur J Gastroenterol Hepatol. 2005;17:1205–12.View ArticlePubMedGoogle Scholar
  25. Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol. 2008;103:1257–62.View ArticlePubMedGoogle Scholar
  26. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461–7.View ArticlePubMedGoogle Scholar
  27. Marie I, Ducrotte P, Denis P, Hellot MF, Levesque H. Outcome of small-bowel motor impairment in systemic sclerosis - a prospective manometric 5-yr follow-up. Rheumatology (Oxford). 2007;46:150–3.View ArticleGoogle Scholar
  28. Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther. 2004;19:687–94.View ArticlePubMedGoogle Scholar
  29. Minami T, Nishibayashi H, Shinomura Y, Matsuzawa Y. Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol. 1996;31:855–9.View ArticlePubMedGoogle Scholar
  30. Lock G, Holstege A, Lang B, Scholmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol. 1997;92:763–71.PubMedGoogle Scholar
  31. Itou H, Iizuka M, Shindo K, Konno S, Watanabe S. A case of pseudoobstruction of the intestine associated with scleroderma dramatically responding to antibiotics. J Gastroenterol. 2006;41:711–2.View ArticlePubMedGoogle Scholar
  32. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol. 2006;2:134–44.View ArticlePubMedGoogle Scholar
  33. Terashima K, Shioyama Y, Nomoto S, Ohga S, Nonoshita T, Ohnishi K, et al. A case of radiation fibrosis appearing as, mass-like consolidation after SBRT with elevation of serum CEA. Case Rep Med. 2010;2010:986706.PubMed CentralPubMedGoogle Scholar
  34. Nakajima N, Sugawara Y, Kataoka M, Hamamoto Y, Ochi T, Sakai S, et al. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Ann Nucl Med. 2013;27:261–70.View ArticlePubMedGoogle Scholar
  35. Niccoli Asabella A, Nicoletti A, Altini C, Notaristefano A, Lastilla G, Rubini G. 18F-FDG positron emission tomography/computed tomography in the diagnosis and post-therapeutic treatment in a patient with an early stage of retroperitoneal fibrosis. Mol Imaging Radionucl Ther. 2013;22:60–2.View ArticlePubMed CentralPubMedGoogle Scholar
  36. Nishiyama Y, Yamamoto Y, Dobashi H, Kameda T. Clinical value of 18F-fluorodeoxyglucose positron emission tomography in patients with connective tissue disease. Jpn J Radiol. 2010;28:405–13.View ArticlePubMedGoogle Scholar

Copyright

© Saigusa et al.; licensee Springer. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.